RxDoctor Payments Data

Kofi Quist, MD

Neurology with Special Qualifications in Child Neurology · Indianapolis, INNPI 1295933349

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.2% of the total across 823 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations.

$17,828in general payments, 2019–2025

Across 823 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2K
  • UCB, Inc.$2K
  • Jazz Pharmaceuticals Inc.$2K
  • AbbVie$1K
  • Biogen$809
  • Lilly USA, LLC$704
  • plus $9K from 54 others

What the payments were for

  • Travel & lodging$1,4508%
  • Food & beverage$16,25491%
  • Education$1241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Livanova USA, Inc.22$2,461
UCB, Inc.120$2,095
Jazz Pharmaceuticals Inc.55$1,640
AbbVie(2 entities)87$1,340
Biogen39$809
Lilly USA, LLC55$704
Teva Pharmaceuticals USA, Inc.40$629
Pfizer48$566
Neurelis, Inc.19$565
Amgen17$512
Catalyst Pharmaceuticals, Inc.23$496
SK Life Science, Inc.17$477
Greenwich Biosciences, Inc.12$358
Novartis21$350
Sunovion Pharmaceuticals Inc.32$306
Eisai Inc.18$298
Neurocrine Biosciences, Inc.12$255
Axsome Therapeutics, Inc.9$245
Lundbeck LLC9$220
Argenx US, Inc.7$219
AstraZeneca6$194
Takeda Pharmaceuticals U.S.A., Inc.9$183
Banner Life Sciences, LLC9$169
Biohaven Pharmaceutical Holding Company Ltd.12$160
Supernus Pharmaceuticals, Inc.10$159
Alnylam Pharmaceuticals Inc.6$142
Harmony Biosciences LLC5$142
Mallinckrodt Hospital Products Inc.3$134
Sumitomo Pharma America, Inc.7$133
Genentech USA, Inc.6$129
Vanda Pharmaceuticals Inc.7$126
Grifols USA, LLC5$101
Biocodex, Inc.1$100
Avanir Pharmaceuticals, Inc.5$98
EMD Serono, Inc.5$89
MDD US Operations, LLC5$85
Octapharma USA, Inc.4$81
Amneal Pharmaceuticals LLC5$80
Sanofi4$76
Cycle Pharmaceuticals Inc3$61
ANI Pharmaceuticals, Inc.2$60
Acorda Therapeutics, Inc3$58
Abbott3$50
Johnson & Johnson2$48
Impel Pharmaceuticals Inc.2$48
Aprecia Pharmaceuticals, LLC3$45
Ipsen Biopharmaceuticals, Inc3$43
Medtronic3$42
Azurity Pharmaceuticals, Inc.2$42
PTC Therapeutics, Inc.2$40
Inspire Medical Systems, Inc.1$37
TG Therapeutics, Inc.2$36
Otsuka America Pharmaceutical, Inc.2$36
Avadel CNS Pharmaceuticals, LLC1$28
Tanabe Pharma America, Inc.1$26
Springworks Therapeutics, Inc.1$26
Biohaven Pharmaceuticals, Inc.1$23
Aquestive Therapeutics, Inc.1$20
Upsher-smith Laboratories LLC1$18
Acadia Pharmaceuticals Inc1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,828 in reported general payments places this provider in the 80th percentile of 25 neurology with special qualifications in child neurology providers in Indiana.

See all neurology with special qualifications in child neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$567,834
Medicare patients
91
Services billed
12,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trokendi XrTopiramate17$17,760
BriviactBrivaracetam12$16,964
Topiramate ErTopiramate17$10,858
Clobazam22$7,903
Oxcarbazepine34$6,802
Lacosamide11$2,682
Levetiracetam21$2,101
Lamotrigine42$915
Topiramate16$289
Trazodone Hcl19$250
Gabapentin18$171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Supernus Pharmaceuticals, Inc.Trokendi Xr$159$17,76017 claims
UCB, Inc.Briviact$2,095$16,96412 claims
Upsher-smith Laboratories LLCTopiramate$18$28916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 25 neurology with special qualifications in child neurology providers in Indiana.

Other neurology with special qualifications in child neurology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →